Vertex Pharmaceuticals Incorporated (VRTX) |
|
225.55 -0.57 (-0.25%)
|
01-17 16:53 |
|
Open: |
226.59 |
Pre. Close: |
226.12 |
|
High:
|
227.44 |
Low:
|
224.46 |
|
Volume:
|
2,242,187 |
Market Cap:
|
58,652M |
|
|
|
|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
228.925 - 231.122 |
231.122 - 232.451 |
|
Low:
|
219.717 - 222.635 |
222.635 - 224.399 |
|
Close:
|
222.228 - 226.945 |
226.945 - 229.797 |
|
Technical analysis |
as of: 2021-01-15 4:46:49 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 271.60 One year: 279.98 |
| Support: |
Support1: 220.93 Support2: 183.81 |
| Resistance: |
Resistance1: 232.54 Resistance2: 239.71 |
| Pivot: |
231.12  |
| Moving Average: |
MA(5): 228.56 MA(20): 232.29
MA(100): 239.48 MA(250): 251.88 |
| MACD: |
MACD(12,26): -0.16 Signal(9): 0.94 |
| Stochastic oscillator: |
%K(14,3): 24.40 %D(3): 34.82 |
| RSI: |
RSI(14): 43.54 |
| 52-week: |
High: 306.08 Low: 197.47 Change(%): -3.6 |
| Average Vol(K): |
3-Month: 187166 10-Days: 185270 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.VRTX has closed above bottom band by 12.1%. Bollinger Bands are 49.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to VRTX's normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 15 Jan 2021
Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know - Nasdaq
Thu, 14 Jan 2021
Vertex Pharmaceuticals Incorporated (VRTX) Stock: How Does it Score on Fundamental Metrics? - InvestorsObserver
Mon, 11 Jan 2021
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) - Seeking Alpha
Mon, 11 Jan 2021
Vertex Pharmaceuticals To Present At The J.P. Morgan Healthcare Conference; Webcast At 9:10 AM ET - Nasdaq
Fri, 08 Jan 2021
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq
Thu, 07 Jan 2021
Vertex Pharmaceuticals (NASDAQ:VRTX) Cut to "Sell" at BidaskClub - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
260 |
| Shares Float (M) |
260 |
|
% Held by Insiders
|
0.09 |
|
% Held by Institutions
|
95.68 |
|
Shares Short (K)
|
3,250 |
|
Shares Short P. Month (K)
|
2,750 |
Stock Financials |
|
EPS
|
10.200 |
|
EPS Est This Year
|
1.630 |
|
EPS Est Next Year
|
2.890 |
|
Book Value (p.s.)
|
31.260 |
|
Profit Margin
|
44.91 |
|
Operating Margin
|
44.67 |
|
Return on Assets (ttm)
|
17.8 |
|
Return on Equity (ttm)
|
40.2 |
|
Qtrly Rev. Growth
|
62.0 |
|
Gross Profit (p.s.)
|
7.153 |
|
Sales Per Share
|
23.035 |
|
EBITDA (p.s.)
|
10.691 |
|
Qtrly Earnings Growth
|
1060.40 |
|
Operating Cash Flow (M)
|
3,210 |
|
Levered Free Cash Flow (M)
|
2,070 |
Stock Valuations |
|
PE Ratio
|
22.11 |
|
PEG Ratio
|
0.36 |
|
Price to Book value
|
7.22 |
|
Price to Sales
|
9.79 |
|
Price to Cash Flow
|
18.27 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
